A phase I trial of imatinib (GLEEVEC), hydroxyurea and RAD001 for patients with recurrent malignant glioma

被引：0
|
作者：
Desjardins, A.
Quinn, J. A.
Rich, J. N.
Vredenburgh, J. J.
Sathornsumetee, S.
Gururangan, S.
Friedman, A. H.
Berg, W.
Egorin, M. J.
Salvado, A.
Friedman, H. S.
Reardon, D. A.
机构：
[1] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA
[2] Novartis Pharmaceut Corp, E Hanover, NJ USA
[3] Duke Univ, Med Ctr, Durham, NC USA
来源：
NEURO-ONCOLOGY | 2006年 / 8卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：441 / 441
页数：1
相关论文
共 50 条
  • [1] A phase I trial of imatinib, hydroxyurea and RAD001 for patients with recurrent malignant glioma.
    Reardon, D.
    Quinn, J. A.
    Rich, J. N.
    Vredenburgh, J. J.
    Desjardins, A.
    Sathornsumetee, S.
    Gururangan, S.
    Egorin, M. J.
    Salvado, A.
    Friedman, H. S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 77S - 77S
  • [2] Final report: Phase I trial of imatinib mesylate, hydroxyurea, and vatalanib for patients with recurrent malignant glioma (MG)
    Kirkpatrick, J. P.
    Rich, J. N.
    Vredenburgh, J. J.
    Desjardins, A.
    Quinn, J. A.
    Gururangan, S.
    Sathornsumetee, S.
    Egorin, M. J.
    Friedman, H. S.
    Reardon, D. A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] VANDETANIB, IMATINIB MESYLATE, AND HYDROXYUREA FOR RECURRENT MALIGNANT GLIOMA: A PHASE I STUDY
    Desjardins, Annick
    Vredenburgh, James J.
    Gururangan, Sridharan
    Peters, Katherine B.
    Friedman, Allan H.
    Friedman, Henry
    Reardon, David A.
    [J]. NEURO-ONCOLOGY, 2009, 11 (05) : 634 - 634
  • [4] PHASE I STUDY OF VANDETANIB, IMATINIB MESYLATE, AND HYDROXYUREA FOR RECURRENT MALIGNANT GLIOMA
    Reardon, David A.
    Vredenburgh, James. L.
    Desjardins, Annick
    Gururangan, Sridharan
    Peters, Katherine B.
    Boulton, Susan T.
    [J]. NEURO-ONCOLOGY, 2009, 11 (06) : 946 - 946
  • [5] Phase I study of vandetanib, imatinib mesylate, and hydroxyurea for recurrent malignant glioma
    Kirkpatrick, J. P.
    Vredenburgh, J. J.
    Desjardins, A.
    Gururangan, S.
    Peters, K. B.
    Boulton, S. T.
    Friedman, A. H.
    Friedman, H. S.
    Reardon, D. A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] Imatinib mesylate (Gleevec) plus hydroxyurea: An effective regimen in the treatment of recurrent malignant glioma: Phase 2 study results
    Reardon, DA
    Quinn, J
    Rich, J
    Vredenburgh, J
    Desjardins, A
    Sathornsumetee, S
    Salvado, A
    Nikolova, Z
    Bigner, D
    Friedman, H
    [J]. NEURO-ONCOLOGY, 2005, 7 (03) : 291 - 291
  • [7] Phase II trial of imatinib mesylate (GLEEVEC) and hydroxyurea for adults with recurrent/progressive meningioma
    Goli, Krishna
    Bota, Daniela
    Desjardins, Annick
    Rich, Jeremy
    Vredenburgh, James
    Quinn, Jennifer
    Sathornsumetee, Sith
    Salvado, August
    Friedman, Henry
    Reardon, David
    [J]. NEURO-ONCOLOGY, 2007, 9 (04) : 519 - 519
  • [8] Phase II trial of imatinib mesylate plus hydroxyurea in the treatment of patients with malignant glioma
    Reardon, D
    Friedman, A
    Herndon, J
    Quinn, J
    Rich, J
    Vredenburgh, J
    Badruddoja, M
    Desjardins, A
    Sampson, J
    Gururangan, S
    Dowell, J
    Affronti, M
    Allen, D
    Jackson, S
    Zeigler, K
    Silverman, S
    Tourt-Uhlig, S
    Silverman, S
    Salvado, A
    Nikolova, Z
    Bigner, D
    Friedman, H
    [J]. NEURO-ONCOLOGY, 2004, 6 (04) : 381 - 381
  • [9] Phase I trial with carboplatin and RAD001 in metastatic breast cancer
    Eucker, J.
    Schwarzlose-Schwarck, S.
    Martus, P.
    Regierer, A. C.
    Schulz, C. O.
    Liu, H.
    Scholz, C. W.
    Schefe, J. H.
    Possinger, K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] A phase I trial of RAD001 in combination with cetuximab in patients with advanced solid tumors
    Avadhani, A. N.
    Flaherty, K.
    Rosen, M.
    Veronese, M. L.
    Harlacker, K.
    Johnson, S. W.
    Sherman, E.
    Griggs, W.
    Divgi, C. R.
    O'Dwyer, P. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345